Keyword: Jardiance

With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

Lilly CEO David Ricks says casting off Elanco will allow it to allocate more capital to its human health efforts.

J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.

In a phase 3 study, Novo said oral semaglutide helped diabetes patients manage their blood sugar levels better than Jardiance. 

Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.

Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.